2Q14 Results: Isagen – Underperform
Worse than expected operating performance due to higher power purchases.
Price: COP 3,240; Target Price: COP 3,060
Ideas get bigger when you share them...
July 31, 2014 (www.investorideas.com newswire) We expected a difficult quarter for Isagen due to complicated hydrological conditions, and consequently we anticipated the company would make lower power sales to avoid power purchases at historically high prices, maintaining the margins at similar levels than those observed in 2Q13. However, this scenario didn’t materialize and the higher revenues ended up being reflected in higher costs, which in turn deteriorated profitability. Isagen generated 2,414 GWh in the 2Q14, a 5.0% lower generation than that observed in the same period of 2013. Nevertheless, revenues grew 20.4% y/y due to higher power sales. Those higher sales had to be covered with higher power purchases which grew 117.6% y/y in a period in which the power spot price was at historical highs (2Q14 average power spot price: 364,4 COP/kWh). Thus, Isagen posted a sharp fall in EBITDA (-26.3% y/y) and Net income (-23.8% y/y), and the EBITDA margin stood at 20.9%, way below that observed in 1Q14 (45.1%) and our estimates for this quarter (33.2%).
In the full year, the bad financial results in 2Q14 were offset by the sound financial results in 1Q14 and the company close 1H14 in line with our initial expectations in terms of EBITDA. We maintain our 2014 T.P. of COP 3,060 and our UNDERPERFORM rating. However, we highlight that the market price of Isagen continues disconnected from the company's fundamentals and fair value and it is driven by speculation on the results of the sale process of the government's stake. The auction is scheduled August 22nd, and according to the rules of the process, the buyer should make a public tender (OPA) benefiting minority shareholders two and a half months after the auction.
La información contenida en este mensaje es confidencial y para conocimiento exclusivo del destinatario. La información y opiniones contenidas en este mensaje pertenecen únicamente al remitente, excepto cuando en el cuerpo del mensaje se establezca lo contrario y el remitente esté autorizado para enviar dicha información con carácter definitivo y oficial de Credicorp Capital. La información relacionada con su cuenta, los extractos, informes financieros y de productos, sólo será vinculante en la medida en que sea remitida por los canales y en los formatos que Credicorp Capital determine. Las opiniones, conclusiones o cualquier otra clase de información contenida en este correo no relacionadas con los fines del negocio de Credicorp Capital, deben entenderse como personales y bajo ninguna circunstancia son avaladas por Credicorp Capital. Si usted ha recibido este mensaje por error por favor proceda a eliminarlo, y notificar al remitente. De cualquier manera, usted no debe usar, divulgar, revelar, distribuir, imprimir, copiar o adulterar en forma parcial o total este mensaje. Credicorp Capital no se hace responsable por la eventual transmisión de virus o programas dañinos por este medio. Credicorp Capital, no se responsabiliza por eventuales daños o alteraciones como consecuencia de la recepción o uso del presente mensaje.
To View Complete Report: Isagen
This news is published on the Investorideas.com Newswire and its syndicated partner network
Get free news alerts:
Sign up here
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.